The positive effect of targeting S100A9 has been observed in many chronic inflammatory diseases with abnormal tissue repair, such as pulmonary fibrosis (29), renal fibrosis (30), atherogenesis (31), and systemic sclerosis phenotype (32). The gene discussed is S100A9; the disease is systemic sclerosis.